Physician profile
Savitri Singh
NPI 1902190432
$1,661.70
in general payments reported to CMS, 2019-2025
17 companies · $282 in 2025
The $282 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $575 · 2021: $20.54 · 2022: $471 · 2023: $133 · 2024: $180 · 2025: $282.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $595.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $594.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $242.24 | 2022 | |
| Corcept Therapeutics | $203.44 | 2024-2025 | Korlym |
| Pfizer INC. | $181.11 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $125.84 | 2022 | |
| Avanir Pharmaceuticals, INC. | $125.00 | 2019 | |
| Allergan, INC. | $122.52 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $121.43 | 2019 | |
| Lilly USA, LLC | $117.28 | 2023-2025 | Zepbound, Mounjaro |
| Janssen Pharmaceuticals, INC | $103.20 | 2022 | |
| Exact Sciences Corporation | $58.33 | 2024-2025 | Cologuard Collection Kit |
| Intra-Sana Laboratories | $57.07 | 2024 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
| Merck Sharp & Dohme LLC | $45.63 | 2019-2021 | |
| La Jolla Pharmaceutical Company | $38.81 | 2023 | Xerava |
| Fisher Scientific Company L.L.C. | $35.93 | 2023 | Procalcitonin |
| Novo Nordisk INC | $31.15 | 2023-2024 | Rybelsus, Ozempic |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $28.65 | 2023 | Qulipta |
| Shield Therapeutics INC | $24.07 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Savitri Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.